Antonio Silvani

Dr. Antonio Silvani

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2015 in JAMA
Verified
Journal Article
Open access
PDF file
RSRoger Stupp
Roger Stupp
STSophie Taillibert
Sophie Taillibert
AKAndrew Kanner
Andrew Kanner
SKSantosh Kesari
Santosh Kesari
DSDavid M. Steinberg
David M. Steinberg
ZRZvi Ram
Zvi Ram
Glioblastoma is the most devastating primary malignancy of the central nervous system in adults. Standard treatment consists of maximal safe surgical resection or a diagnostic biopsy, followed by radiotherapy (60 Gy) with concomitant daily temozolomide chemotherapy, and then maintenance treatment with temozolomide for 6 to 12 months.1 However, most patients will die within 1 to 2 years. Median progression-free survival from diagnosis of 6.2 to 7.5 months and median overall survival from diagnosis of 14.6 to 16.7 months have been reported in clinical trials.1-4 The reported 2- and 5-year survival rates5 are 27% and 10%, respectively. During the last decade, all attempts to improve the outcome for patients with glioblastoma have failed when evaluated in large randomized trials.2-4,6,7

1 September 2005 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
CCC. Calatozzolo
C. Calatozzolo
MGMaurizio Gelati
Maurizio Gelati
ECEmilio Ciusani
Emilio Ciusani
FSF. L. Sciacca
F. L. Sciacca
BPBianca Pollo
Bianca Pollo
ASAndrea Salmaggi
Andrea Salmaggi

2 March 2010 in Neurology
Verified
Journal Article
Closed access
PDF file
APAndrea Pace
Andrea Pace
DGDiana Giannarelli
Diana Giannarelli
EGE. Galiè
E. Galiè
ASA. Savarese
A. Savarese
SCS. Carpano
S. Carpano
FCF. Cognetti
F. Cognetti
Objective: The clinical use of cisplatin chemotherapy is limited by severe peripheral neurotoxicity reported in up to 90% of patients receiving a cumulative dose higher than 300 mg/m2. The present study evaluates the neuroprotective effect of antioxidant supplementation (vitamin E) in patients treated with cisplatin chemotherapy.

1 May 2007 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
Marica EoliMarica Eoli
Marica Eoli
FMFrancesca Menghi
Francesca Menghi
MBMaria Grazia Bruzzone
Maria Grazia Bruzzone
TSTiziana De Simone
Tiziana De Simone
LVLorella Valletta
Lorella Valletta
GFGaetano Finocchiaro
Gaetano Finocchiaro
Purpose: Recent data suggest that methylation of the DNA repair gene O6-methylguanine DNA methyltransferase (MGMT), by increasing the chemosensitivity of glioblastoma multiforme, is significantly associated with improved prognosis. Results in contradiction with these findings, however, are present in the literature and the clinical and genetic context framing MGMT methylation is poorly characterized. Experimental Design: To address these issues, we have investigated the MGMT methylation status, clinical and magnetic resonance imaging characteristics, and relevant genetic features (loss of heterozygosity on 17p and 19q, EGFR amplification, and p53 mutations) in a retrospective study on 86 patients affected by glioblastoma multiforme: 72 patients had a clinical history indicating de novo insurgence of the tumor and the remaining 14 were secondary glioblastoma multiforme. Results: MGMT methylation was detected by methylation-specific PCR in 41 of 86 cases (47.7%; Meth+). Progression-free survival and overall survival were significantly longer in Meth+ than in Meth− patients [10 versus 7 months (P = 0.003, log-rank test) and 18 versus 14 months (P = 0.0003, log-rank test), respectively]. Mixed-nodular enhancement at magnetic resonance imaging was significantly more frequent in Meth+ and secondary glioblastoma multiforme and ring enhancement in Meth− and primary glioblastoma multiforme (P < 0.005). MGMT methylation was more present in secondary glioblastoma multiforme (P = 0.006) and associated with loss of heterozygosity on 17p and/or 19q (P = 0.005). Conclusions: These observations suggest that MGMT methylation is part of a genetic signature of glioblastomas that developed from lower-grade gliomas.

1 May 2003 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
ASAndrea Salmaggi
Andrea Salmaggi
Marica EoliMarica Eoli
Marica Eoli
SFSimona Frigerio
Simona Frigerio
ASAntonio Silvani
Antonio Silvani
MGMaurizio Gelati
Maurizio Gelati
ABAmerigo Boiardi
Amerigo Boiardi

1 April 2005 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
AGAnna Rita Giovagnoli
Anna Rita Giovagnoli
ASAntonio Silvani
Antonio Silvani
ECE Colombo
E Colombo
ABA Boiardi
A Boiardi
Objectives: To assess patients with recurrent high grade brain glioma with the aim of evaluating facets of quality of life (QOL) and their association with mood, cognition, and physical performance. Methods: Ninety four glioma patients (four groups with different duration of glioma recurrence) were compared with 24 patients with other chronic neurological diseases and 48 healthy subjects. The Functional Living Index—Cancer (FLIC) provided QOL self evaluations, and standardised scales and neuropsychological tests assessed physical performance, mood, and cognition. Results: In glioma patients, factor analysis of the FLIC items documented five domains: Psychological well being, Role/sociability, Inner experience of disease, Isolation/sharing, and Nausea. Higher FLIC total scores were related to better cognition, physical performances, and mood, and lower grading; poorer Psychological well being and worse Inner experience of disease to depressed mood; minor Role/sociability to worse cognitive and physical performances and higher grading; worse Nausea to longer disease duration. Compared with healthy subjects, all glioma groups were cognitively impaired and more anxious, and two groups with short duration of recurrence were also more depressed. Patients with chronic neurological diseases showed worse mood and cognitive abilities compared with healthy subjects, but performed attention tests better than glioma patients. Glioma and chronic disease patients showed similar FLIC scores and autonomy. Conclusions: These results show that QOL of recurrent high grade glioma patients is multifaceted and determined by multiple factors. Disease severity does not necessarily eliminate the possibility of expressing personal feelings and opinions which could provide criteria for clinical decision making and psychological support.